Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.
BACKGROUND: Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT),...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797095390593417216 |
|---|---|
| author | Seo, S Englund, J Nguyen, J Pukrittayakamee, S Lindegardh, N Tarning, J Tambyah, P Renaud, C Went, G Jong, d Boeckh, M |
| author_facet | Seo, S Englund, J Nguyen, J Pukrittayakamee, S Lindegardh, N Tarning, J Tambyah, P Renaud, C Went, G Jong, d Boeckh, M |
| author_sort | Seo, S |
| collection | OXFORD |
| description | BACKGROUND: Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model. METHODS: We first analysed the pharmacokinetics (PKs) of TCAD therapy in healthy volunteers. We then performed a pilot study of TCAD therapy in patients undergoing chemotherapy or haematopoietic cell transplantation. AMT (75 mg), OSL (50 mg) and RBV (200 mg) were administered three times a day for 10 days. The safety and PKs of TCAD therapy were monitored. RESULTS: The PKs of TCAD therapy in healthy volunteers was shown to be similar to the PKs of each drug individually from a single dose. In the pilot study, six immunocompromised patients received TCAD therapy and one patient received OSL monotherapy. All but one patient completed 10 days of TCAD therapy without side effects; one patient receiving TCAD was withdrawn from the study because of respiratory failure and ultimately recovered. Viral load was decreased after TCAD therapy, despite the presence of either AMT- or OSL-resistant virus in two cases. One patient with 2009 influenza A/H1N1 receiving OSL monotherapy developed confirmed OSL resistance during treatment. CONCLUSIONS: TCAD therapy had similar PKs to each individual antiviral during monotherapy following a single dose and can be administered safely in immunocompromised patients. |
| first_indexed | 2024-03-07T04:27:09Z |
| format | Journal article |
| id | oxford-uuid:cd0a9e91-b399-4510-82dd-3d0085593775 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:27:09Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:cd0a9e91-b399-4510-82dd-3d00855937752022-03-27T07:25:59ZCombination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cd0a9e91-b399-4510-82dd-3d0085593775EnglishSymplectic Elements at Oxford2013Seo, SEnglund, JNguyen, JPukrittayakamee, SLindegardh, NTarning, JTambyah, PRenaud, CWent, GJong, dBoeckh, MBACKGROUND: Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model. METHODS: We first analysed the pharmacokinetics (PKs) of TCAD therapy in healthy volunteers. We then performed a pilot study of TCAD therapy in patients undergoing chemotherapy or haematopoietic cell transplantation. AMT (75 mg), OSL (50 mg) and RBV (200 mg) were administered three times a day for 10 days. The safety and PKs of TCAD therapy were monitored. RESULTS: The PKs of TCAD therapy in healthy volunteers was shown to be similar to the PKs of each drug individually from a single dose. In the pilot study, six immunocompromised patients received TCAD therapy and one patient received OSL monotherapy. All but one patient completed 10 days of TCAD therapy without side effects; one patient receiving TCAD was withdrawn from the study because of respiratory failure and ultimately recovered. Viral load was decreased after TCAD therapy, despite the presence of either AMT- or OSL-resistant virus in two cases. One patient with 2009 influenza A/H1N1 receiving OSL monotherapy developed confirmed OSL resistance during treatment. CONCLUSIONS: TCAD therapy had similar PKs to each individual antiviral during monotherapy following a single dose and can be administered safely in immunocompromised patients. |
| spellingShingle | Seo, S Englund, J Nguyen, J Pukrittayakamee, S Lindegardh, N Tarning, J Tambyah, P Renaud, C Went, G Jong, d Boeckh, M Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. |
| title | Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. |
| title_full | Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. |
| title_fullStr | Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. |
| title_full_unstemmed | Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. |
| title_short | Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. |
| title_sort | combination therapy with amantadine oseltamivir and ribavirin for influenza a infection safety and pharmacokinetics |
| work_keys_str_mv | AT seos combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT englundj combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT nguyenj combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT pukrittayakamees combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT lindegardhn combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT tarningj combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT tambyahp combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT renaudc combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT wentg combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT jongd combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics AT boeckhm combinationtherapywithamantadineoseltamivirandribavirinforinfluenzaainfectionsafetyandpharmacokinetics |